Acrobiosystems Co

Acrobiosystems Co Diluted EPS

The Diluted Earnings per Share of Acrobiosystems Co (301080.SZ) as of Nov 21, 2026 is 0.99 CNY. In the previous year, Diluted Earnings per Share was 0.74 CNY — a change of 33.70% (higher).

Diluted EPS

0.99CNY

YoY

33.70%

Last updated:

Diluted Earnings per Share of Acrobiosystems Co is 2025 0.99 CNY. Diluted Earnings per Share of Acrobiosystems Co was 2024 0.74 CNY. It decreases by 33.70% higher compared to the previous year.

The Acrobiosystems Co Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
0.06 CNY
Jan 1, 2019
0.07 CNY
Jan 1, 2020
0.69 CNY
Jan 1, 2021
1.04 CNY
Jan 1, 2022
2.55 CNY
Jan 1, 2023
1.28 CNY
Jan 1, 2024
0.74 CNY
Jan 1, 2025
0.99 CNY
The Acrobiosystems Co Diluted EPS history
YEARDiluted EPSYoY
0.99CNY+33.70%
0.74CNY-42.41%
1.28CNY-49.74%
2.55CNY+145.58%
1.04CNY+50.34%
0.69CNY+943.79%
0.07CNY+10.14%
0.06CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Diluted Earnings per Share of Acrobiosystems Co is 0.99 CNY in 2025.

Diluted Earnings per Share of Acrobiosystems Co changed from 0.74 CNY to 0.99 CNY, representing a 33.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co